Vanderbilt researchers have designed a low-cost, point-of-care device that non-invasively monitors peripheral venous pressure (PVP) to ensure proper placement of peripheral intravenous (PIV) catheters in patients. Use of this device will ensure proper administration of intravenous fluids and intravenous drugs. The device will also prevent the administration of fluid and potent pharmacologic agents into the subcutaneous tissue or fascia, commonly known as "IV infiltration."
The present system developed by Vanderbilt researchers provides a combination of a base laser pump connected to a laser surgical probe via a connection assembly. The surgical probe has a disposable tip wherein the Er:YAG lasing occurs. This system is useful in laser surgeries involving high precision and appropriate power levels. In particular, intraocular surgeries could benefit from the use of such a system.
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely-used anti-inflammatory and anti-pyretic therapeutic agents to treat human diseases. However, long-term use of NSAIDs comes with risks. Many NSAIDs are COX-1 inhibitors, which are associated with significant GI toxicities. The Marnett Lab at Vanderbilt University has developed new derivatives of NSAIDs that retain their protective effects but do not cause debilitating and potentially fatal toxicities.
REDCap (Research Electronic Data Capture) is a secure web application for building and managing online surveys and databases. Despite its broad potential application, the primary function is for Electronic Data Capture, specifi cally for Clinical Trial Management solutions. REDCap is a globally implemented platform at more than 906 institutional partners from CTSA, GCRC, RCMI and other institutions in 73 countries. The REDCap application allows users to build and manage online surveys and databases quickly and securely, and is currently in production use or development build-status for more than 92,000 projects with over 119,000 users spanning numerous research focus areas across the consortium.
The invention is a device which permits the direct quantification of leachable organic constituents from within solid materials. It is expected that the device will be used in landfills and in other environments where measurements are central to the evaluation of the environmental compatibility of solid materials (e.g., sediments, soils, solidified waste forms) containing organic constituents that have the potential to degrade water resources of to be taken up by biota and the food chain. The invention is designed to simplify current difficulties in assessing leaching of organic constituents with low aqueous solubility.
Transcend is a model-based diagnosis system for fault detection and isolation of abrupt faults in complex to very complex engineered systems. It applies models of dynamic system behavior to obtain accurate predictions for measured transients and compares predictions with actual observations to distill the true cause for the faulty behavior. To successfully perform diagnosis, Transcend needs a dynamic model of the system.
This proportional actuator developed at Vanderbilt University is a superior source of controllable power for mobile robots. It utilizes monopropellant or hypergolic bipropellant fuel sources in a controlled manner for more efficient and effective untethered mobile robots performing human mechanical tasks over a prolonged period of time.
A flexible endoscope for ophthalmic orbital surgery is presented. The endoscope has illuminating fiber, image fiber and a free conduit to deliver purge gas/fluid in addition to instruments such as ablation instruments, coagulating instrument or a medication delivery instrument.
Vanderbilt researchers have developed a low-cost, high sensitivity sensor based on a porous silicon (PSi) membrane waveguide. This sensor is designed to be a cost-effective alternative to conventional fiber optic and SPR sensors for both biosensing and chemical sensing applications.
Commercial routes to industrially important pharmaceutical and agrichemical compounds can often be developed more economically when separation of enantiomeric intermediates/ products is possible. Vanderbilt University seeks to license technologies, originally invented at DuPont, that allow such separations to be performed via novel biocatalysts. Vanderbilt's technology can be used for the production of chiral tertiary esters and/ or enantiomeric amides. In the case of the former class of compounds, our technology is somewhat unique in its ability to operate on carbonyl groups alpha to a tertiary center. See the following description for more information about the current status of this technology and the associated patent estate.
It is estimated that approximately 30% of men have reduced fertility and 2% are totally infertile. Despite these large numbers relatively little is know about the molecular bases of male infertility. On the flip side of male infertility is the need for male contraception. Currently there are no reversible, convenient male contraceptives available. In order to develop male contraceptives and acquire a greater understanding of male fertility there is a need to develop animal models to study the molecular basis and pathways that regulate and control male fertility. Vanderbilt researchers have developed a model mouse system to study male fertility. There research focuses on the epididymus, which is the area that spermatozoa acquire the ability to move and fertilize. For this region to be functional tissue and cell specific gene regulation must occur. These investigators have discovered one such gene regulated within this area, mEP17. These researchers can fuse either mouse or human EP17 or just the regulatory regions of either EP17 to reporter genes and the resulting fusion can be used to screen for substances that regulate this gene and affect male fertility. This system becomes a powerful tool to identify drugs which affect this gene and be potential male contraceptives. In addition polypeptides generated to this gene may be used as vaccines for male contraceptives.
This invention is directed to cloning and characterization of BVES (blood vessel/epicardial substance), a cDNA expressed in developing and adult heart and skeletal muscle cells in chick, mouse and human. Also provided are applications of BVES as a marker for cardiovascular or skeletal muscle diseases.
A method of testing a candidate composition for PAI-1 inhibition activity is disclosed. The method includes the steps of obtaining a transgenic non-human warm blooded vertebrate animal having incorporated into its genome a PAI-1 gene encoding a biologically active PAI-1 polypeptide, the PAI-1 gene being present in the genome in a copy number effective to confer over-expression in the transgenic non-human animal of the PAI-1 polypeptide; administering the composition to the transgenic non-human animal; and observing the transgenic non-human animal for determination of a change in the transgenic non-human animal indicative of inhibition of the activity of PAI-1. A transgenic non-human animal useful in such a method is also disclosed, as is a PAI-1 transgene construct encoding a biologically active PAI-1 polypeptide useful for preparing the transgenic non-human animal.